PureTech Health/$PRTC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About PureTech Health
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
Ticker
$PRTC
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
56
ISIN
US7462371060
Website
PureTech Health Metrics
BasicAdvanced
$444M
93.65
$0.21
0.90
-
Price and volume
Market cap
$444M
Beta
0.9
52-week high
$25.00
52-week low
$13.30
Average daily volume
4.5K
Financial strength
Current ratio
9.333
Quick ratio
9.186
Long term debt to equity
37.127
Total debt to equity
40.59
Interest coverage (TTM)
-13.54%
Profitability
EBITDA (TTM)
-134.062
Gross margin (TTM)
-1,333.89%
Net profit margin (TTM)
1,108.33%
Operating margin (TTM)
-2,814.19%
Effective tax rate (TTM)
-16.86%
Revenue per employee (TTM)
$90,000
Management effectiveness
Return on assets (TTM)
-13.10%
Return on equity (TTM)
6.41%
Valuation
Price to earnings (TTM)
93.654
Price to revenue (TTM)
1,036.594
Price to book
0.79
Price to tangible book (TTM)
0.79
Price to free cash flow (TTM)
-37.241
Free cash flow yield (TTM)
-2.69%
Free cash flow per share (TTM)
-52.81%
Growth
Revenue change (TTM)
44.98%
Earnings per share change (TTM)
-187.50%
3-year revenue growth (CAGR)
-34.76%
10-year revenue growth (CAGR)
8.07%
3-year earnings per share growth (CAGR)
-0.21%
10-year earnings per share growth (CAGR)
-8.49%
What the Analysts think about PureTech Health
Analyst ratings (Buy, Hold, Sell) for PureTech Health stock.
Bulls say / Bears say
PureTech Health maintains a strong cash position with $366.8 million in cash, cash equivalents, and short-term investments as of December 31, 2024, providing an operational runway into at least 2027. (webull.com)
The company has a robust pipeline, having developed 29 therapeutics and therapeutic candidates, including three FDA-approved treatments, indicating a strong foundation for future growth. (tradingview.com)
PureTech's Founded Entities raised $397.5 million in 2024, with over 88% coming from third parties, demonstrating strong external validation and financial support for its ventures. (webull.com)
In the first half of 2024, PureTech Health reported a significant decline in revenue to $288,000 from $3.2 million the previous year, alongside a widened pretax loss of $55.0 million, raising concerns about financial performance. (shareprices.com)
At the June 2025 Annual General Meeting, 27.51% of shareholders voted against the Directors’ Remuneration Report, indicating notable shareholder dissatisfaction with executive compensation. (stocktitan.net)
Institutional investors, holding 73% of PureTech Health, may exert pressure on the company following a 15% drop in share price, potentially leading to strategic shifts or asset sales. (simplywall.st)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
PureTech Health Financial Performance
Revenues and expenses
PureTech Health Earnings Performance
Company profitability
PureTech Health News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for PureTech Health stock?
PureTech Health (PRTC) has a market cap of $444M as of July 22, 2025.
What is the P/E ratio for PureTech Health stock?
The price to earnings (P/E) ratio for PureTech Health (PRTC) stock is 93.65 as of July 22, 2025.
Does PureTech Health stock pay dividends?
No, PureTech Health (PRTC) stock does not pay dividends to its shareholders as of July 22, 2025.
When is the next PureTech Health dividend payment date?
PureTech Health (PRTC) stock does not pay dividends to its shareholders.
What is the beta indicator for PureTech Health?
PureTech Health (PRTC) has a beta rating of 0.9. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.